News
Onco360®, the nation’s leading independent specialty pharmacy, has been selected as a pharmacy partner by Deciphera ...
4d
MedPage Today on MSNBTK Inhibitors for Multiple SclerosisMultiple sclerosis (MS) includes both peripheral and central nervous system (CNS) inflammation, and an anti-inflammatory ...
1d
Clinical Trials Arena on MSNEnrolment concludes in Phase III trial of Dizal’s sunvozertinib for NSCLCThe trial is being carried out in 16 nations and regions, including Asia, North America, Europe, and South America.
Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...
Cabozantinib is a vascular endothelial growth factor receptor tyrosine kinase inhibitor, a drug used as a therapy for several ...
Golidocitinib demonstrated promising efficacy in maintaining and enhancing tumor response in peripheral T-cell lymphoma (PTCL ...
Ibtrozi had a 90% response rate in treatment naïve adults with locally advanced or metastatic ROS1-positive non-small cell ...
Findings from HERTHENA-Lung02 showed that the key secondary endpoint of overall survival did not meet statistical significance.
Glenmark Pharmaceuticals announced its plan to launch the cancer treatment drug zanubrutinib in India after receiving ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results